- Home
- HCM vs CPRI Comparison
HCM vs CPRI Comparison
Compare HCM & CPRI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | HCM | CPRI |
|---|---|---|
| Founded | 2000 | 1981 |
| Country | Hong Kong | United Kingdom |
| Employees | 1796 | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Apparel |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.3B | 2.4B |
| IPO Year | N/A | 2011 |
Fundamental Metrics
Financial Performance| Metric | HCM | CPRI |
|---|---|---|
| Price | $11.42 | $18.81 |
| Analyst Decision | Sell | Buy |
| Analyst Count | 1 | 13 |
| Target Price | $13.75 | ★ $26.62 |
| AVG Volume (30 Days) | 52.1K | ★ 2.6M |
| Earning Date | 03-05-2026 | 05-27-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 111.40 |
| EPS | N/A | ★ 1.14 |
| Revenue | N/A | ★ $3,474,000,000.00 |
| Revenue This Year | $20.60 | N/A |
| Revenue Next Year | $15.62 | $1.81 |
| P/E Ratio | ★ $5.49 | $16.63 |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $9.77 | $16.72 |
| 52 Week High | $19.50 | $28.27 |
Technical Indicators
Market Signals| Indicator | HCM | CPRI |
|---|---|---|
| Relative Strength Index (RSI) | 57.30 | 47.71 |
| Support Level | $9.77 | $16.82 |
| Resistance Level | $15.59 | $22.08 |
| Average True Range (ATR) | 0.28 | 0.80 |
| MACD | 0.19 | -0.17 |
| Stochastic Oscillator | 89.30 | 23.14 |
Price Performance
Historical ComparisonAbout HCM HUTCHMED (China) Limited
HUTCHMED (China) Ltd is a biopharmaceutical company engaged in the discovery, development, and commercialization of targeted therapies and immunotherapies for the treatment of cancer and immunological diseases. The company has a portfolio of several cancer drug candidates currently in clinical studies world-wide and an extensive commercial infrastructure in its home market, China. The company operates in two reportable segments: Oncology/Immunology and Other Ventures.
About CPRI Capri Holdings Limited
Capri Holdings is a marketer, distributor, and retailer of upscale accessories and apparel in the Americas, Europe, and Asia. Michael Kors, Capri's original and largest brand by sales, offers handbags, footwear, and apparel through more than 700 company-owned stores, wholesale, and e-commerce. Jimmy Choo (acquired in 2017) is best known for women's luxury footwear. Its products are sold in more than 200 company-operated stores. John Idol has served as Capri's CEO since 2003.